Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022–01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin. - Pointreau, Y.; Larnaudie, A.; Sun, X.S.; Rolland, F.; Boisselier, P.; Tao, Y.; Hugo, C.; Bourhis, J. (Radiotherapy & Oncology, 2026)